- Home
- SGI vs RPRX Comparison
SGI vs RPRX Comparison
Compare SGI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGI
- RPRX
- Stock Information
- Founded
- SGI 1846
- RPRX 1996
- Country
- SGI United States
- RPRX United States
- Employees
- SGI N/A
- RPRX N/A
- Industry
- SGI Home Furnishings
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGI Consumer Discretionary
- RPRX Health Care
- Exchange
- SGI Nasdaq
- RPRX Nasdaq
- Market Cap
- SGI 17.4B
- RPRX 16.0B
- IPO Year
- SGI N/A
- RPRX 2020
- Fundamental
- Price
- SGI $82.76
- RPRX $37.31
- Analyst Decision
- SGI Strong Buy
- RPRX Strong Buy
- Analyst Count
- SGI 6
- RPRX 4
- Target Price
- SGI $87.17
- RPRX $44.50
- AVG Volume (30 Days)
- SGI 1.6M
- RPRX 2.3M
- Earning Date
- SGI 11-06-2025
- RPRX 11-05-2025
- Dividend Yield
- SGI 0.72%
- RPRX 2.36%
- EPS Growth
- SGI N/A
- RPRX 54.86
- EPS
- SGI 1.40
- RPRX 2.32
- Revenue
- SGI $5,993,400,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- SGI $52.67
- RPRX $35.14
- Revenue Next Year
- SGI $5.74
- RPRX $1.24
- P/E Ratio
- SGI $59.15
- RPRX $16.03
- Revenue Growth
- SGI 23.05
- RPRX 3.02
- 52 Week Low
- SGI $47.46
- RPRX $24.05
- 52 Week High
- SGI $88.15
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- SGI 44.81
- RPRX 59.95
- Support Level
- SGI $83.22
- RPRX $36.69
- Resistance Level
- SGI $85.63
- RPRX $37.69
- Average True Range (ATR)
- SGI 1.83
- RPRX 0.63
- MACD
- SGI -0.39
- RPRX 0.13
- Stochastic Oscillator
- SGI 3.64
- RPRX 84.55
About SGI Somnigroup International Inc. Common Stock
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.